Plenaxis "not approvable" response
Praecis says it will consider conducting additional clinical trials following Sept. 10 meeting with FDA to discuss "not approvable" letter for Amgen/Praecis' prostate cancer treatment Plenaxis (abarelix). Possible trials would evaluate the use of currently available hormonal therapies in patients first treated with Plenaxis. Praecis will also conduct a re-analysis of allergic reactions using existing clinical data
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth